A new annual report released by Sun Life, an international financial services organization and the largest independent stop-loss provider in the U.S., analyzed 60,000 stop-loss claims from a member database of 6 million people.
The report revealed a number of significant findings, including that cardiovascular disease rose to second place on the list of highest stop-loss claim reimbursements over a four-year period from 2020 to 2023. According to the report, reimbursements for cardiovascular diseases surpassed blood cancers for the first time in 12 years.
Malignant neoplasm (solid tumors) topped the list of highest reimbursements in 2023 followed by cardiovascular disease, newborn/infant care, orthopedics/musculoskeletal care and leukemia/lymphoma and multiple myeloma. The report found that in 2023, U.S. companies received $415.6 million in reimbursements for malignant neoplasm alone.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
